NO20062904L - Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti - Google Patents

Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti

Info

Publication number
NO20062904L
NO20062904L NO20062904A NO20062904A NO20062904L NO 20062904 L NO20062904 L NO 20062904L NO 20062904 A NO20062904 A NO 20062904A NO 20062904 A NO20062904 A NO 20062904A NO 20062904 L NO20062904 L NO 20062904L
Authority
NO
Norway
Prior art keywords
gynecomastia
hydroxy tamoxifen
drug
preparation
treatment
Prior art date
Application number
NO20062904A
Other languages
English (en)
Other versions
NO336463B1 (no
Inventor
Elisabeth Le Nestour
Andrew R Palumbo
Original Assignee
Ascend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03293156A external-priority patent/EP1550440A1/en
Priority claimed from US10/734,640 external-priority patent/US7786172B2/en
Application filed by Ascend Therapeutics Inc filed Critical Ascend Therapeutics Inc
Publication of NO20062904L publication Critical patent/NO20062904L/no
Publication of NO336463B1 publication Critical patent/NO336463B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Oppfinnelsen skaffer til veie fremgangsmåter for behandling og forebygging av gynekomasti ved administrering av 4-hydroksy tamoxifen til en pasient. Når det administreres perkutant til en pasients bryst, konsentteres 4-hydroksy tamoxifen lokalt, og utøver en anti-østtogen effekt. Hos pasienter med gynekomasti, reduserer dette det effektive østtogen-androgen forholdet i brystvevet, for dermed å redusere duktal proliferasjon, epitel og sttomal hyperplasi og smerte. Hos pasienter med risiko for utvikling av gynekomasti, forhindrer 4-hydroksy tamoxifens anti-østrogene effekt, vevsproliferasjon og dens ledsagende smerte.
NO20062904A 2003-12-15 2006-06-21 Anvendelse av 4-hydroksytamoxifen for fremstilling av et medikament for behandling av gynekomasti NO336463B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03293156A EP1550440A1 (en) 2003-12-15 2003-12-15 Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
US10/734,640 US7786172B2 (en) 2002-12-18 2003-12-15 Treatment of mastalgia with 4-hydroxy tamoxifen
PCT/EP2004/014295 WO2005058297A1 (en) 2003-12-15 2004-12-13 Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia

Publications (2)

Publication Number Publication Date
NO20062904L true NO20062904L (no) 2006-06-21
NO336463B1 NO336463B1 (no) 2015-08-31

Family

ID=34702366

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062904A NO336463B1 (no) 2003-12-15 2006-06-21 Anvendelse av 4-hydroksytamoxifen for fremstilling av et medikament for behandling av gynekomasti

Country Status (15)

Country Link
EP (1) EP1694319B1 (no)
JP (1) JP5069469B2 (no)
AT (1) ATE401067T1 (no)
AU (1) AU2004298349B2 (no)
CA (1) CA2549824C (no)
DE (1) DE602004015146D1 (no)
DK (1) DK1694319T3 (no)
ES (1) ES2310765T3 (no)
HK (1) HK1094768A1 (no)
MX (1) MXPA06006834A (no)
NO (1) NO336463B1 (no)
NZ (1) NZ547744A (no)
PL (1) PL1694319T3 (no)
PT (1) PT1694319E (no)
WO (1) WO2005058297A1 (no)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337298B1 (no) * 2004-03-22 2016-03-07 Besins Healthcare Lu Sarl Kjemisk stabile preparater av 4-hydroksytamoksifen

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1748770T3 (da) * 2004-03-22 2008-08-04 Besins Int Lab Behandling og forebyggelse af benign brystsygdom med 4-hydroxy-tamoxifen
MX2007004371A (es) * 2004-10-14 2007-06-07 Besins Int Lab Formulaciones de 4-hidroxitamoxifen en gel.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1210951B1 (en) * 2000-11-30 2005-02-02 Pfizer Products Inc. Composition containing estrogen agonists/antagonists and testosterone for treating a decline in the level of the hormone testosterone
IL158871A0 (en) * 2001-07-31 2004-05-12 Pfizer Prod Inc Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
DE60139625D1 (de) * 2001-12-07 2009-10-01 Besins Int Belgique Gel oder Lösung enthaltend Dihydrotestosterone, deren Herstellungsverfahren und Verwendung
DK1631275T3 (da) * 2003-06-09 2008-08-18 Ascend Therapeutics Inc Behandling og forebyggelse af excessiv ardannelse med 4-hydroxy-tamoxifen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337298B1 (no) * 2004-03-22 2016-03-07 Besins Healthcare Lu Sarl Kjemisk stabile preparater av 4-hydroksytamoksifen

Also Published As

Publication number Publication date
JP2007529420A (ja) 2007-10-25
DK1694319T3 (da) 2008-11-17
MXPA06006834A (es) 2006-09-04
AU2004298349B2 (en) 2010-02-25
AU2004298349A1 (en) 2005-06-30
NZ547744A (en) 2009-09-25
DE602004015146D1 (de) 2008-08-28
EP1694319B1 (en) 2008-07-16
ATE401067T1 (de) 2008-08-15
ES2310765T3 (es) 2009-01-16
WO2005058297A1 (en) 2005-06-30
NO336463B1 (no) 2015-08-31
CA2549824A1 (en) 2005-06-30
PT1694319E (pt) 2008-10-24
CA2549824C (en) 2012-03-13
PL1694319T3 (pl) 2009-01-30
HK1094768A1 (en) 2007-04-13
JP5069469B2 (ja) 2012-11-07
EP1694319A1 (en) 2006-08-30

Similar Documents

Publication Publication Date Title
NO20054526L (no) Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
RU2012148710A (ru) Органическое соединение для применения при лечении рака печени
Kästner et al. Removal of polyacrylamide gel (Aquamid®) from the lip as a solution for late-onset complications: our 8-year experience
SE0300098D0 (sv) Use of cyclin D1 inhibitors
NO20062904L (no) Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti
EA201270298A1 (ru) Способ лечения злокачественной опухоли
de la Peña et al. Subfascial gluteal augmentation
EA200600284A1 (ru) Дооперационное лечение послеоперационной боли
ATE391499T1 (de) 4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen
Senderoff Practice-based patient management strategies in gluteal augmentation with implants
Honnor The management of chronic oedema in palliative care
Harmer Breast cancer. Part 3: advanced cancer and psychological implications
RU2222319C2 (ru) Способ регионарной лимфостимуляции и обезболивания при лимфедеме нижних конечностей
Struik Improving Treatment Accuracy and Reducing Side Effects of Breast Conserving Therapy to increase patient satisfaction in early stage breast cancer
Jandali et al. Treatment of Lipedema
Khallaf BUTTOCK AUGMENTATION WITH FAT TRANSERFERE: EXPERIENCE WITH 200 CASES
McLemore et al. X-ray appearance of subcutaneous gemstones as part of alternative/holistic medicine: a case report and review of the literature
Feins et al. Staged skin and subcutaneous excision
de Fátima Guerreiro Godoy et al. Clinical treatment of arm lymphedema in an outpatient setting: Two years of follow up.
Beam et al. Median neuropathy associated with acupoint stimulation strip
Vidal et al. Triton tumor in a patient with neurofibromatosis-1: a clinical case
BR112012013719A2 (pt) uso de transferrina no tratamento de ß-talassemias
Blugerman et al. Minimal Invasive Calf Augmentation

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASCEND THERAPEUTICS INC, LU

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BESINS HEALTHCARE LUXEMBOURG SARL, LU

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BESINS HEALTHCARE LUXEMBOURG SARL, LU